Electrocardiographic Findings in Children Treated with Leuprolide Acetate for Precocious Puberty: Does it Cause Prolonged QT?
PDF

Original Article

Electrocardiographic Findings in Children Treated with Leuprolide Acetate for Precocious Puberty: Does it Cause Prolonged QT?

J Clin Res Pediatr Endocrinol 2024;16(4):426-430 DOI: 10.4274/jcrpe.galenos.2024.2024-2-8
, , , ,
PDF
Permissions

Abstract

Objective

Central precocious puberty (CPP) is treated with long-acting gonadotropin releasing hormone (GnRH) analogues (GnRHa). Some adult patients undergoing GnRHa treatment experienced prolonged QT syndrome, which is associated with an increased risk of serious cardiac events, such as myocardial infarction, stroke, arrhythmias, and sudden cardiac death.

Methods

Seventy-four patients, aged between 5 and 11 years and diagnosed with CPP but with no other concomitant disease or medication use, underwent electrocardiogram (ECG) assessment. They had been receiving 3.75 mg leuprolide acetate (Lucrin® Depot) injections every 28 days for at least three months.

Results

The ECGs of all patients showed a corrected QT (QTc) interval within normal limits, consistent with the data for healthy Turkish children of the same age and gender. No other pathological physical examination or ECG findings were observed. Furthermore, there was no significant difference in QTc interval when adjusted for age, anthropometric data, or the duration or cumulative dose of the treatment.

Conclusion

The study found no correlation between QTc interval values and age, treatment duration, total cumulative dose, and anthropometric data. These findings suggest that cardiovascular adverse events associated with GnRHa treatment may be related to age and other underlying physiopathological conditions in adults rather than being directly due to the drug.

Keywords: Precocious puberty, leuprolide acetate, children, ECG, prolonged QT

Read the full text

5 sections · 2 tables · PDF

Create your free account to read the full text.

  • Full text with figures and tables
  • PDF and supplementary files
  • Access on every Galenos journal
Get free access

Already have an account?

Sign in
or
Continue with Google

One Galenos account works on every Galenos journal site.

References

1

Cheuiche AV, da Silveira LG, de Paula LCP, Lucena IRS, Silveiro SP. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr. 2021;180:3073-3087. Epub 2021 Mar 21

2

Eugster EA. Treatment of Central Precocious Puberty. J Endocr Soc. 2019;3:965-972.

3

Abbasi D, Faiek S, Shetty S, Khan E. Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT. Cureus. 2020;12:e9041.

4

Kim J, Freeman K, Ayala A, Mullen M, Sun Z, Rhee JW. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice. Curr Oncol Rep. 2023;25:965-977. Epub 2023 Jun 5

5

Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men. Clin Drug Investig. 2017;37:873-879.

6

Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565-573. Epub 2013 Nov 1

7

Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2015;7:280-293.

8

Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A Comprehensive Online Calculator for Pediatric Endocrinologists: ÇEDD Çözüm/TPEDS Metrics. J Clin Res Pediatr Endocrinol. 2017;9:182-184. Epub 2017 Apr 26

9

Dahlberg P, Diamant UB, Gilljam T, Rydberg A, Bergfeldt L. QT correction using Bazett’s formula remains preferable in long QT syndrome type 1 and 2. Ann Noninvasive Electrocardiol. 2021;26:e12804. Epub 2020 Oct 18

10

Lester RM, Paglialunga S, Johnson IA. QT Assessment in Early Drug Development: The Long and the Short of It. Int J Mol Sci. 2019;20:1324.

11

Semizel E, Oztürk B, Bostan OM, Cil E, Ediz B. The effect of age and gender on the electrocardiogram in children. Cardiol Young. 2008;18:26-40. Epub 2007 Dec 20

12

Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943-1948.

13

Charles I Berul. Acquired long QT syndrome: Definitions, pathophysiology, and causes. Up To date (ed. Samuel Asirvatham); last updated Sep 21, 2022.

14

Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.

15

Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal. 2012;2012:212178. Epub 2012 Apr 19

16

Klivinyi C, Bornemann-Cimenti H. Pain medication and long QT syndrome. Korean J Pain. 2018;31:3-9. Epub 2018 Jan 2

17

Waldner RC, Doulla M, Atallah J, Rathwell S, Grimbly C. Leuprolide Acetate and QTc Interval in Gender-Diverse Youth. Transgend Health. 2023;8:84-88.

18

Miller BS, Kamjob M; on behalf of the Drug and Therapeutics Committee. Risk of Prolonged QT Interval with Gonadotropin Releasing Hormone Agonists. Mclean, VA: Pediatric Endocrine Society, 2017.